Literature DB >> 7945221

Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.

Z B Moola1, M D Scawen, T Atkinson, D J Nicholls.   

Abstract

This study shows that the antigenicity of Erwinia chrysanthemi L-asparaginase can be reduced by site-directed mutagenesis. Ten B-cell epitopes of the enzyme were identified using synthetic hexapeptides and polyclonal antisera from rabbits and mice. The region 282GIVPPDEELP292 near the C-terminus was an immunodominant epitope. Binding of two hexapeptides (283IVPPDE288 and 287DEELPG292) to the antibodies was dependent on Pro285, and Pro286, since their replacement by almost any other amino acid resulted in reduced binding. The other residues were less important for binding the antibodies, as binding was relatively unaffected by amino acid substitutions. Three site-directed mutant enzymes, P285T (proline-285-->threonine etc.), P286Q and E288A, were expressed in Escherichia coli. The purified enzymes had subunit M(r) values of 35,000. The pI values of P285T, P286Q and the wild-type enzymes were 8.6, and that for the mutant E288A was 9.2. The kcat. and Km values for the mutants P286Q and E288A with L-asparagine and L-glutamine were comparable with those of the wild-type enzyme. The Km values for the mutant P285T with both substrates was similar to that of the wild-type enzyme, whereas the kcat. was reduced by 2-fold with L-asparagine and by 4-fold with L-glutamine. The change proline-->threonine reduced the antigenicity of the enzyme by 8-fold, as shown in sandwich e.l.i.s.a.s. using monoclonal antibodies raised against the wild-type enzyme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945221      PMCID: PMC1137318          DOI: 10.1042/bj3020921

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia.

Authors:  O B Eden; M P Shaw; J S Lilleyman; S Richards
Journal:  Med Pediatr Oncol       Date:  1990

2.  Altering the antigenicity of proteins.

Authors:  H Alexander; S Alexander; E D Getzoff; J A Tainer; H M Geysen; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

3.  The pMTL nic- cloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing.

Authors:  S P Chambers; S E Prior; D A Barstow; N P Minton
Journal:  Gene       Date:  1988-08-15       Impact factor: 3.688

4.  Immunogenic structure of the influenza virus hemagglutinin.

Authors:  N Green; H Alexander; A Olson; S Alexander; T M Shinnick; J G Sutcliffe; R A Lerner
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

5.  Asparaginase and glutaminase activities of bacteria.

Authors:  H E Wade; H K Robinson; B W Phillips
Journal:  J Gen Microbiol       Date:  1971-12

6.  Nucleotide sequence of the Erwinia chrysanthemi NCPPB 1066 L-asparaginase gene.

Authors:  N P Minton; H M Bullman; M D Scawen; T Atkinson; H J Gilbert
Journal:  Gene       Date:  1986       Impact factor: 3.688

7.  Chemical modification of L-asparaginase with a comb-shaped copolymer of polyethylene glycol derivative and maleic anhydride.

Authors:  Y Kodera; H Tanaka; A Matsushima; Y Inada
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

8.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

Authors:  A Abuchowski; G M Kazo; C R Verhoest; T Van Es; D Kafkewitz; M L Nucci; A T Viau; F F Davis
Journal:  Cancer Biochem Biophys       Date:  1984-06

9.  Cognitive features of continuous antigenic determinants.

Authors:  H M Geysen; T J Mason; S J Rodda
Journal:  J Mol Recognit       Date:  1988-02       Impact factor: 2.137

10.  Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion.

Authors:  J G KIDD
Journal:  J Exp Med       Date:  1953-12       Impact factor: 14.307

View more
  16 in total

Review 1.  What makes a good new therapeutic L-asparaginase?

Authors:  Angela Beckett; David Gervais
Journal:  World J Microbiol Biotechnol       Date:  2019-09-24       Impact factor: 3.312

2.  Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.

Authors:  L N Ramya; Krishna Kanth Pulicherla
Journal:  Pathol Oncol Res       Date:  2015-03-06       Impact factor: 3.201

3.  Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage.

Authors:  Georgia A Kotzia; Katerina Lappa; Nikolaos E Labrou
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

Review 4.  Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia.

Authors:  Nanxiang Wang; Wenhui Ji; Lan Wang; Wanxia Wu; Wei Zhang; Qiong Wu; Wei Du; Hua Bai; Bo Peng; Bo Ma; Lin Li
Journal:  RSC Med Chem       Date:  2022-01-12

5.  Cell-cycle inhibition by Helicobacter pylori L-asparaginase.

Authors:  Claudia Scotti; Patrizia Sommi; Maria Valentina Pasquetto; Donata Cappelletti; Simona Stivala; Paola Mignosi; Monica Savio; Laurent Roberto Chiarelli; Giovanna Valentini; Victor M Bolanos-Garcia; Douglas Scott Merrell; Silvia Franchini; Maria Luisa Verona; Cristina Bolis; Enrico Solcia; Rachele Manca; Diego Franciotta; Andrea Casasco; Paola Filipazzi; Elisabetta Zardini; Vanio Vannini
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

6.  Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.

Authors:  Ranjit Kumar Mehta; Shikha Verma; Rashmirekha Pati; Mitali Sengupta; Biswajit Khatua; Rabindra Kumar Jena; Sudha Sethy; Santosh K Kar; Chitra Mandal; Klaus H Roehm; Avinash Sonawane
Journal:  J Biol Chem       Date:  2013-12-02       Impact factor: 5.157

7.  Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.

Authors:  Alejandro Huerta-Saquero; Zahaed Evangelista-Martínez; Angélica Moreno-Enriquez; Ernesto Perez-Rueda
Journal:  Bioengineered       Date:  2012-08-16       Impact factor: 3.269

8.  Pentacyclic Triterpenoids Inhibit IKKβ Mediated Activation of NF-κB Pathway: In Silico and In Vitro Evidences.

Authors:  Kalpesh R Patil; Purusottam Mohapatra; Harun M Patel; Sameer N Goyal; Shreesh Ojha; Chanakya N Kundu; Chandragouda R Patil
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

9.  Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.

Authors:  David Gervais; Tim Corn; Andrew Downer; Stuart Smith; Alan Jennings
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

10.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  A Mayer; S K Sharma; B Tolner; N P Minton; D Purdy; P Amlot; G Tharakan; R H J Begent; K A Chester
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.